Molecular pathogenesis and systemic therapies for hepatocellular carcinoma

Josep M. Llovet, Roser Pinyol, Robin K. Kelley, Anthony El-Khoueiry, Helen L. Reeves, Xin Wei Wang, Gregory J. Gores, Augusto Villanueva

Research output: Contribution to journalReview articlepeer-review


Hepatocellular carcinoma (HCC) remains one of the most prevalent and deadliest cancers. The poor outcome associated with HCC is dramatically changing due to the advent of effective systemic therapies. Here we discuss the molecular pathogenesis of HCC, molecular classes and determinants of heterogeneity. In addition, effective single-agent and combination systemic therapies involving immunotherapies as standard of care are analyzed. Finally, we propose a flowchart of sequential therapies, explore mechanisms of resistance and address the need for predictive biomarkers.

Original languageEnglish (US)
Pages (from-to)386-401
Number of pages16
JournalNature Cancer
Issue number4
StatePublished - Apr 2022

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Molecular pathogenesis and systemic therapies for hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this